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Endothelial adherence and subsequent transendothelial migra-
tion of circulating monocytes is an early event in the generation
of atherosclerotic arterial lesions (1). Taking up lipids that
have accumulated in the subendothelial compartment, these
monocytes become the lipid-laden macrophages recognized as
foam cells in histologic sections of early atheromas. Monocytes
that infiltrate these lesions provide chemotactic stimuli that
attract other leukocytes to the same site, with the result that
atheromatous lesions continue to provoke an intense inflam-
matory response through all phases of their development (2).
Infiltrating monocytes may express tissue factor and provide a
local stimulus for thrombus formation (3). Metalloproteinases,
released by activated macrophages that have infiltrated the
shoulders and base of mature plaques, can also hydrolyze the
tissue matrix proteins that bind atheromas to the arterial wall.
Rupture of these connective tissue attachments also predis-
poses to arterial thrombosis (4,5). The likelihood of this grim
scenario has been significantly reduced by the development of
safe and effective therapeutic agents that reduce biosynthesis
and, consequently, circulating levels of cholesterol. Inhibitors
of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) re-
ductase, the rate-limiting enzyme in cholesterol biosynthesis,
have been particularly well accepted both because of their
efficacy and their tolerability.
The report by Weber et al. (6) in this issue of the Journal
provides evidence that HMG-CoA reductase, in addition to its
pivotal role in cholesterol biosynthesis, also regulates impor-
tant functions used by activated monocytes to invade endothe-
lium. They show that treatment with HMG-CoA reductase
inhibitors in vitro, and in vivo, depresses expression and
function of leukocyte cell surface molecules required for
monocytes to adhere to confluent endothelial monolayers.
Thus, in addition to reducing circulating levels of the lipids
largely responsible for provoking the vascular inflammatory
response that results in atherosclerosis, these enzyme inhibi-
tors provide a second benefit: They interfere directly with key
mechanisms necessary for leukocytes to carry out this inflam-
matory response. Although the report by Weber et al. (6) only
provides information concerning the ability of treated mono-
cytes to adhere to endothelial monolayers, one may speculate
that other proinflammatory activities, including the ability of
treated monocytes to migrate across vascular endothelial bar-
riers in response to chemotactic stimuli, may also be impaired.
Other investigators (7) have shown that the response of
monocytoid cells to chemotactic stimuli is reduced by treat-
ment with HMG-CoA reductase inhibitors. The reason that
these therapeutic agents modulate monocyte functions is that
HMG-CoA reductase generates mevalonate, the precursor of
a complex series of isoprenoids that posttranslationally modify
(isoprenylate) proteins that regulate diverse biochemical path-
ways (8). Isoprenoids are required to maintain NADPH oxi-
dase activity in granulocytes and for activated macrophages to
generate hydrogen peroxide. Isoprenoids, produced by this
enzyme, do not affect monocyte interleukin (IL)-1-beta pro-
duction, but they do modulate monocyte/macrophage produc-
tion of IL-8 and the proinflammatory cytokine IL-6 (8).
Considering the diverse and redundant functions of granulo-
cytes and monocytes and the fact that research concerning the
effect of HMG-CoA reductase inhibitors on leukocyte behav-
ior is still in its infancy, it is not yet clear how useful mevalonate
synthesis inhibitors may be if used solely as anti-inflammatory
agents. Nevertheless, the report by Weber et al. (6) suggests
that further investigation of their ability to regulate leukocyte-
mediated responses is warranted.
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Abbreviations and Acronyms
HMG-CoA 5 3-hydroxy-3-methyl-glutaryl coenzyme A
IL 5 interleukin
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